IVVD Invivyd, Inc.

Nasdaq invivyd.com


$ 1.53 $ 0.02 (1.32 %)    

Thursday, 06-Nov-2025 16:27:59 EST
QQQ $ 612.70 $ -11.61 (-1.86 %)
DIA $ 469.79 $ -3.83 (-0.81 %)
SPY $ 671.63 $ -7.27 (-1.07 %)
TLT $ 89.62 $ 0.80 (0.9 %)
GLD $ 365.86 $ -0.44 (-0.12 %)
$ 1.54
$ 1.61
$ 1.49 x 200
$ 1.54 x 1,213
$ 1.45 - $ 1.65
$ 0.35 - $ 2.74
3,320,862
na
359.01M
$ 1.35
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-28-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-23-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-13-2022 03-31-2022 10-Q
16 03-31-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 09-20-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 invivyd-q3-eps-006-beats-008-estimate-sales-13129m-beat-13100m-estimate

Invivyd (NASDAQ:IVVD) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25...

 hc-wainwright--co-maintains-buy-on-invivyd-raises-price-target-to-10

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Invivyd (NASDAQ:IVVD) with a Buy and raises the price target f...

 hc-wainwright--co-maintains-buy-on-invivyd-raises-price-target-to-10

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Invivyd (NASDAQ:IVVD) with a Buy and raises the price target f...

 d-boral-capital-maintains-buy-on-invivyd-raises-price-target-to-2

D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:IVVD) with a Buy and raises the price target from $1 to $2.

 the-fda-clears-invivyds-investigational-new-drug-application-and-provided-feedback-to-advance-its-revolution--clinical-development-program-for-vyd2311-a-vaccine-alternative-monoclonal-antibody-candidate-to-prevent-covid-infection

The DECLARATION clinical trial is the company's Biologics License Application (BLA)-enabling, Phase 3 pivotal clinical tria...

 cantor-fitzgerald-initiates-coverage-on-invivyd-with-overweight-rating-announces-price-target-of-10

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Invivyd (NASDAQ:IVVD) with a Overweight rating and announces P...

 invivyd-filed-for-350m-mixed-shelf-offering

-SEC Filing

 steven-cohens-biotech-bets-are-getting-bolder--and-smaller

Billionaire hedge fund manager Steven Cohen is diving into small-cap biotech with new stakes in two clinical-stage companies, s...

 point72-hedge-fund-manager-steve-cohen-discloses-8-passive-stake-in-invivyd

-SEC Filing

 hc-wainwright--co-reiterates-buy-on-invivyd-maintains-5-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $5 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION